- Q4 2023 Immunocore Holdings PLC Earnings Call TranscriptFeb 28, 2024$69.21 (-1.76%)Earnings
- Immunocore Holdings PLC at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Immunocore Holdings PLC at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Immunocore Holdings PLC Earnings Call TranscriptAug 10, 2023$61.66 (-3.67%)Earnings
- Immunocore Holdings PLC at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Immunocore Holdings PLC at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Immunocore Holdings PLC at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Q4 2022 Immunocore Holdings PLC Earnings Call TranscriptMar 01, 2023$54.05 (-1.46%)Earnings
- Immunocore Holdings PLC at Citi Virtual Oncology Leadership Summit TranscriptFeb 22, 2023
- Immunocore Holdings PLC at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Immunocore Holdings PLC at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Immunocore Holdings PLC at Jefferies London Healthcare Conference TranscriptNov 17, 2022
- Immunocore Holdings PLC PRAME Investor and Analyst Event AT ESMO 2022 TranscriptSep 09, 2022
- Q2 2022 Immunocore Holdings PLC Earnings Call TranscriptAug 10, 2022$53.95 (+4.27%)Earnings
- Immunocore Holdings PLC at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Immunocore Holdings PLC To Discuss FDA Approval Call TranscriptJan 26, 2022
Q2 2023 Immunocore Holdings PLC Earnings Call Transcript
Greetings. Welcome to the Immunocore Second Quarter 2023 Financial Results and Business Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. At this time, I would like to hand the call over to Clayton Robertson, Head of Investor Relations. Thank you. You may begin.
Thank you. During today's call, we'll be making certain forward-looking statements, including about financial projections, development activities, business strategy and the timing and impact of future events. Actual results could differ materially from those projected by these statements, which are based on management's views as of today and subject to risks and uncertainties, including those noted in our most recent Form 20-F and any 6-Ks we filed with the SEC in the earnings press release we issued this morning. You're cautioned not to place undue reliance on these statements, and Immunocore disclaims any obligation to update them. We will also disclose certain non-IFRS measures on today's call,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)